Pharmaceutical Margins Will Come under Extreme Pressures in 2008 and beyond According to Recent Report State of the Pharmaceutical Industry, 2008

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reports/c83502) has announced the addition of new Decision Resources report State of the Pharmaceutical Industry, 2008 to their offering.

What will pharmaceutical management see when it looks in the mirror in 2008? Amid the pressures and shortcomings of recent industry performance, will management recognize and act upon the opportunities that already exist? Adhering to the status quo is not propelling this industry forward; only real change can accomplish that goal. What should the industry do to improve its performance and outlook? We asked industry leaders—both within and outside of Decision Resources—to offer their opinions on the issues that will both concern and excite the pharmaceutical industry in 2008. Herein you will find their expert commentary, their recommendations, and a Spectrum Scorecard assessing the actions the industry should consider going forward.

Get the Answers You Need to Shape Your Strategy

• Pharmaceutical margins will come under extreme pressures in 2008 and beyond. What major challenges are critically important for the industry to solve? What are potentially the best solutions to address these challenges?
• Pharma is losing ground in the supply and control of information about drugs. What new concepts in information delivery are developing? How has the control of personalized information delivery gripped stakeholders, and how are they using this approach to their advantage?
• Globalization of the pharmaceutical and biotechnology industries in an exciting prospect for change. Why is globalization a double-edged sword? Why will it cost some companies their livelihood and independence, and what implications does this have for Western companies?

Scope

• Opinions from industry experts and thought leaders: expert commentary and analysis from four internal experts including Decision Resources’ president Sarah Fuller and ten external industry consultants and professionals.
• The pharmaceutical Haves and Have-Nots: dwindling pipelines, looming patent expiries, and generics challenges; companies’ coping strategies; and potential changes for former market leaders.
• Communicating information on drugs and health care—the control of information is allpowerful: personalized information, social networking, balanced drug information, evidence-based medicine, counter-detailing.
• Globalization: mature (G7) versus emerging (E7) pharmaceutical markets; offshoring and outsourcing to China versus India; a survey of executives at 40 companies in China and India; the impact of Western multinational companies doing business abroad; contract research organization activities; and Japan’s evolving marketplace.
• Pharmaceutical pricing models: industry pressures and traditional defenses; customer demands for value-for-money, cost-effectiveness models, and evidence-based medicine; what can be gained if companies and health technology assessment agencies work together; a case study of Alzheimer’s drug HTAs; lessons to be learned and new approaches to take.
• Convergence: coalescing technologies and opportunities point to the need to develop new industry business models; human genome sequencing, biomarkers, and targeted therapies; biotech as the innovation engine for pharma; disruptive technology; the need for a clear-cut personalized medicine business model.

Topics Explored:

Executive Summary

Strategic Considerations

Trends and Their Implications for Stakeholders

2008: Charting New Waters

The Haves and the Have-Nots: Propelling Companies Toward Novel Options

Predicting a Growing Divide

Surviving Fallow Periods Will Become More Difficult

Superimposing the Generic Dimension Widens the Have/Have-Not Divide

Coping Strategies Will Force New Business Models

Personalized Information: Who Will Provide It?

Recent Trends in Communicating Information on Drugs and Health Care

Providing Unbiased Drug Information

The Value of Social Networking

Educating Physicians: Evidence-Based Medicine and Counter-Detailing

Globalization: Threat or Opportunity

Expanding into Emerging Pharmaceutical Markets

Different Pharmaceutical Markets Developing in China and India

No Longer Simply a Matter of Cost

Moving Upstream in the R&D Value Chain

Japan’s Evolving Pharmaceutical Marketplace

Growing Impact of Foreign Pharmaceutical Companies

Domestic Japanese Companies: To Merge or Not to Merge?

Striving to Stay Independent

Pharma Pricing 2008: Make or Break

Crumbling Industry Defenses

Emboldened Customer Offensives

Technology Assessment: The Case of Alzheimer’s Drugs

Technology Assessments

The Case of Alzheimer’s Drugs

Actions Going Forward

Convergence: Are We There Yet?

Targeted Therapies

Biomarker-Driven Personalized Medicine: The Way Forward in Cancer Therapy

An Analysis of Industry Trends in Personalized Medicine

Trends Identified by the Diaceutics Google Index

Lack of an Appropriate Business Model

Convergence

Industry Action Items Going Forward

SPECTRUM Pharmaceutical Industry Dynamics 1-3

Pharmaceutical Industry, 2008

Experts Featured:

John Ansell, M.A., principal, John Ansell Consultancy

Cheryl Barton, Ph.D., principal

R. Roman Boutellier, Ph.D., Swiss Federal Institute of Technology, Zurich

Caroline Fielding, deputy managing director, Virgo Health PR

Sarah W. Fuller, president, Decision Resources, Inc.

Jeffrey Gruen, M.D., M.B.A., chief medical officer, Revolution Health

Barrie G. James, Ph.D., principal, Pharma Strategy Consulting

James McDermott, vice president, consulting, Decision Resources, Inc.

Mollie Roth, J.D., corporate counsel, vice president of business development, Diaceutics

Alexander J. Schicker, M.Sc., Swiss Federal Institute of Technology, Zurich

Jeffrey Settleman, Ph.D., professor of medicine at Harvard Medical School and director,

Center for Molecular Therapeutics at the Massachusetts General Hospital Cancer Center

Hiroshi Tashiro, M.Sc., research manager of Decision Resources’ Tokyo office

Fredrik Ullman, M.Sc., Swiss Federal Institute of Technology, Zurich

Prachi Vora, M.P.H., Spectrum program manager, Decision Resources, Inc.

List of Tables

List of Figures

For more information visit http://www.researchandmarkets.com/reports/c83502